Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Synmosa Biopharma Corp (4114) AI Stock Analysis

TW:4114

Synmosa Biopharma Corp

(TPEx:4114)

Select Model
Rating:65Neutral
Price Target:TWD 29.00â–²(4.50% Upside)
Action:initiatedcoverage
Date:11/10/26

The overall stock score of 65 is primarily driven by solid financial performance from revenue growth and balance sheet improvement, offset by cash flow volatility. Technical indicators reflect bearish momentum despite oversold conditions, while valuation offers reasonable support via fair P/E and attractive yield.

Positive Factors
Revenue Growth and ProfitabilityThe multi-year revenue uptrend and renewed growth in 2025 indicate continuing commercial traction across the business. Healthy net profitability provides resources to support research, regulatory activity, and commercialization while strengthening the company’s ability to fund operations over the next several quarters.
Negative Factors
Weak Cash ConversionThe sharp 2025 decline in free cash flow shows that accounting earnings are not consistently translating into cash available for reinvestment or shareholder returns. Persistent volatility could constrain funding flexibility and make future pharmaceutical investment more dependent on operating improvement.

Synmosa Biopharma Corp (4114) vs. SPDR S&P 500 ETF (SPY)

-10%-5%0%5%10%15%20%TW:4114-3.90%SPY+14.30%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 15.02B
Dividend Yield
3.06%
Average Volume (3M)
839.84K
Price to Earnings (P/E)
17.7
Beta (1Y)
0.31
Revenue Growth
11.40%
EPS Growth
9.36%
Country
TW
Employees
495
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Synmosa Biopharma Corp Business Overview & Revenue Model

Company Description

Synmosa Biopharma Corporation, established in Taipei, Taiwan, in 1980, operates as a dedicated specialty pharmaceutical enterprise. The company manages the entire lifecycle of pharmaceutical and healthcare products, from research and development to m...

Synmosa Biopharma Corp Financial Statement Overview

Summary

Consistent revenue growth and a strengthened balance sheet with reduced debt-to-equity ratio are positives, although volatile cash flows present some concerns.

Income Statement

76Positive

Balance Sheet

84Very Positive

Cash Flow

52Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.68B6.19B5.55B5.14B4.39B3.23B
Gross Profit2.72B2.54B2.40B2.12B1.83B1.29B
EBITDA1.03B1.12B1.06B1.01B1.10B507.92M
Net Income775.69M821.85M684.68M594.83M799.09M303.86M
Balance Sheet
Total Assets15.28B13.99B12.30B11.73B11.20B10.32B
Cash, Cash Equivalents and Short-Term Investments2.78B2.93B1.89B1.65B1.42B993.13M
Total Debt3.36B2.52B2.55B2.44B3.37B3.46B
Total Liabilities5.41B3.89B3.91B3.63B4.55B4.22B
Stockholders Equity8.65B8.76B7.21B6.71B5.31B4.71B
Cash Flow
Free Cash Flow150.99M130.44M510.97M242.16M445.92M312.74M
Operating Cash Flow355.79M411.57M780.62M511.93M630.25M454.86M
Investing Cash Flow-1.14B-663.53M-336.80M-717.87M-69.33M73.33M
Financing Cash Flow345.94M964.20M-187.55M37.24M-347.94M-297.57M

Synmosa Biopharma Corp Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:4114 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:6620TW:662070OutperformTWD 20.83B66.76―1.52%――
TW:4114TW:411465NeutralTWD 14.97B17.66―3.06%11.40%9.36%
TW:1789TW:178957NeutralTWD 16.01B904.98―1.45%-4.75%-90.91%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:4147TW:414747NeutralTWD 16.47B-103.67――7.02%25.72%
TW:6547TW:654740UnderperformTWD 16.94B-409.93――44.37%78.11%

* General Sector Average

Performance Comparison

-50%0%50%TW:4114TW:1789TW:4147TW:6547TW:6589TW:6620Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:4114 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:4114Synmosa Biopharma Corp27.75-1.94-6.53%
TW:1789Scinopharm Taiwan, Ltd.20.002.6014.92%
TW:4147TaiMed Biologics Inc.61.90-6.60-9.64%
TW:6547Medigen Vaccine Biologics Corp.46.358.9523.93%
TW:6589EirGenix, Inc.51.70-30.20-36.87%
TW:6620Handa Pharmaceuticals Inc136.5017.9515.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026